The letter "C" probably stands for "Chimeric". In
this case half mouse half human.
The number 2
probably is the orignial microplate number that harbored
the original cell that was used to propagate the cell
line that gave rise to C2B8. Each microplate has
ninety six wells,12 columns and eight rows. Each column
has an assigned number( 1 through 12) and each row
has an assigned letter (A throught H). So the
original well on the microplate that had the original cell
that gave rise to the cell line for making antibody
was located in row B column 8. So now we have
Chimeric;plate #2;row B column 8.
Hey I full of all
kinds of useless information
Then you may want to rummage through old annual
reports for idph to get clues on how the deal was done.
But companies don't exactly have to tell the truth,
the whole truth, and nothing but the truth on these
I'm trying to get a handle on how a company
forges an agreement to market a drug and Rituxan is very
similar (monoclonal antibody used to fight cancer) in
nature to another drug that is building up to this point
- and eventual FDA approval.
Rituxan, previously know as the C2B8 antibody, is a
single-agent monoclonal antibody therapy for the treatment of
relapsed or refractory low-grade or follicular,
CD20-positive B-cell non-Hodgkin's lymphoma.
LDP-03, is a humanized monoclonal antibody to the
leukocyte antigen CAMPATH, which is for the treatment of
chronic lymphocytic leukemia ("CLL"). LDP-03 combats CLL
by selectively depleting lymphocytes while sparing
hematopoietic stem cells.
This selective depletion
permits the body to retain needed hematopoietic stem
cells that are the precursors to, and repopulate the
blood with, leukocytes and preserve normal immune
function. LDP-03 binds to the antigen CD52, which is
expressed almost exclusively on lymphocytes and which is
not expressed on hematopoietic stem cells, and
destroys the lymphocytes.
By attacking the antigen
CD52 and its lymphocytes, LDP-03 is more selective
than currently approved drugs for lymphomas and
leukemias which indiscriminately deplete rapidly-dividing
cells, including both lymphocytes and hematopoietic stem
IDEC Corporation manufactures products that
simplify interaction between humans and machines.
With a comprehensive line of products, from relays and
switches to sensors and micro PLCs, IDEC provides critical
solutions for industrial equipment manufacturers as well as
advanced technical applications.
international headquarters in Sunnyvale, California, IDEC has
served customers throughout the world for over 23 years.
I don't think IDEC has a webpage. Considerable
info is available on the Genentech webpage,
particularly the "full prescribing information", aka the
"package insert" that comes with the product at the
Of course, that is medical information. Details on
chemistry, how it works (to the extent they know),
indications, warnings, adverse events, etc. What information
are you looking for?